Cas:62542-44-3 1-methyl-2-oxoquinoline-4-carboxylic acid manufacturer & supplier

Chemical Name:1-methyl-2-oxoquinoline-4-carboxylic acid

CAS.NO:62542-44-3

Synonyms:1-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylic acid;1-methyl-2-oxohydroquinoline-4-carboxylic acid;BB_NC-1954

Molecular Formula:C₁₁H₉NO₃

Molecular Weight:203.19400

HS Code:2933790090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:59.30000

Exact Mass:203.05800

LogP:1.23670

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,BB_NC-1954 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-methyl-2-oxohydroquinoline-4-carboxylic acid Use and application,BB_NC-1954 technical grade,usp/ep/jp grade.

Related News: In 2016, in order to promote the innovative development, transformation and upgrading of the pharmaceutical industry, the Development and Reform Commission led the compilation of the Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry, which put forward requirements for all aspects of the medical industry and specifically proposed support for the field of chemical raw materials. . 1-methyl-2-oxoquinoline-4-carboxylic acid manufacturer The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs. 1-methyl-2-oxoquinoline-4-carboxylic acid supplier Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 1-methyl-2-oxoquinoline-4-carboxylic acid vendor Green Valley said it would launch the drug ��very soon�� in China. The company also aims to roll out a phase-3 clinical trial with sites in the United States, Europe and Asia in early 2020 to facilitate global regulatory approval of the drug. 1-methyl-2-oxoquinoline-4-carboxylic acid factory Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body.